GSK plc Sponsored ADR (GSK)
Here's Why GSK (GSK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
US FDA approves GSK's drug for liver disease related itching
The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused by a type of liver disease, the company said on Thursday, making it the first treatment greenlit for the condition.
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
GSK, with Luke Miels becoming its new CEO in early 2026, continues its successful expansion into the oncology and cardiovascular drugs markets. So, on February 25, GSK announced that it acquired 35Pharma for $950 million, which, in turn, is developing HS235 for the treatment of pulmonary hypertension. Moreover, the performance of its HIV blockbuster, Dovato, also did not disappoint me.
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
GSK gets US FDA approval for expanded use of RSV vaccine
British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus.
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma
GSK licenses linerixibat to Alfasigma for cholestatic pruritus in PBC, securing $300M upfront and potential milestone payments as the drug awaits FDA review.
GSK sells rights to rare liver disease drug for up to $690m
The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader liver disease pipeline GSK PLC (LSE:GSK, NYSE:GSK), the British pharmaceutical giant, has agreed to license worldwide rights to its experimental liver disease drug linerixibat to Italian pharma company Alfasigma in a deal worth up to $690 million. Under the terms of the agreement, GSK will receive an upfront payment of $300 million, a further $100 million upon US Food and Drug Administration (FDA) approval, $20 million on EU and UK approval, and up to $270 million in sales-based milestone payments, as well as tiered double-digit royalties on net sales.
GSK licenses liver disease drug to Italy's Alfasigma
GSK has agreed to sell its worldwide rights to develop and commercialise its experimental liver disease drug linerixibat to Italian pharmaceutical company Alfasigma for an upfront payment of $300 million, the companies said on Monday.
Is It Too Late to Buy GSK After a 46% Share Price Jump?
GSK has handed investors a remarkable run. Over the past year, the stock climbed roughly 44% from $37.79 to $54.51.
GSK to Buy 35Pharma for $950 Million
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary hypertension that its new owner believes can improve on the safety profile of existing therapies in a market forecast to reach $18 billion by 2032. The asset at the centre of the deal is HS235, an activin signalling inhibitor that has completed phase I healthy volunteer trials and is preparing to enter studies in two forms of the disease: pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.
